SCHEMBL5454030

SCHEMBL5454030

NC(=O)c1c(NC(=O)C2CC2)sc2c(Br)c(O)c(Br)cc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 1/20 0.48
AURKB Q96GD4 1/20 0.48
FLT3 P36888 1/20 0.47
MAPK10 P53779 2/20 0.42
MAPT P10636 1/20 0.40
MAPK1 P28482 1/20 0.39
GFER P55789 1/20 0.39
TNIK Q9UKE5 2/20 0.37
HTT P42858 2/20 0.37
KMT2A Q03164 3/20 0.36
MEN1 O00255 2/20 0.36
LMNA P02545 1/20 0.36
HPGD P15428 1/20 0.36
ALOX15 P16050 1/20 0.36
ALOX12 P18054 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
GSK3B P49841 3/20 0.36
REV1 Q9UBZ9 1/20 0.36
CDK2 P24941 1/20 0.36
GSK3A P49840 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5446326 0.84 MEN1 (0.48) AURKAAURKBFLT3MAPK10MAPT
SCHEMBL5448926 0.82 FLT3 (0.47) AURKAAURKBFLT3MAPK10MAPT
SCHEMBL17611488 0.81 FLT3 (0.46) AURKAAURKBFLT3MAPK10MAPT
SCHEMBL5458422 0.81 AURKA (0.46) AURKAAURKBFLT3MAPK10MAPT
SCHEMBL5467348 0.75 FLT3 (0.47) AURKAAURKBFLT3MAPK10MAPT
SCHEMBL17611413 0.75 FLT3 (0.42) AURKAAURKBFLT3MAPK10MAPT
SCHEMBL5456073 0.74 FLT3 (0.46) AURKAAURKBFLT3MAPK10MAPT
SCHEMBL5450964 0.73 FLT3 (0.48) AURKAAURKBFLT3MAPK10MAPT
SCHEMBL19352846 0.73 KMT2A (0.38) AURKAAURKBMAPTKMT2AMEN1
SCHEMBL5463015 0.72 AURKA (0.46) AURKAAURKBFLT3MAPK10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 AURKA 869/4885AURKB 585/4885FLT3 3509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.